A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

Gynecologic Oncology

Volumn 102, Issue 2, 2006, Pages 300-308

  Hirte, H ^a   Vergote, I B ^b   Jeffrey, J R ^c   Grimshaw, R N ^d   Coppieters, S ^e   Schwartz, B ^f   Tu, D ^g   Sadura, A ^g   Brundage, M ^g   Seymour, L ^g  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Cancer Care Nova Scotia   (Canada)

^e Bayer sa nv Belgium   (Belgium)

^f Bayer Inc   (Canada)

^g Queen's Cancer Research Institute   (Canada)

Author keywords

Inhibitor; Matrix metalloproteinase

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; PACLITAXEL; PHOSPHATE; PLACEBO; POTASSIUM; TANOMASTAT;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BASAL CELL CARCINOMA; BLOOD TOXICITY; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CYTOTOXICITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EDEMA; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; NAUSEA; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TISSUE SECTION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; MIDDLE AGED; ORGANIC CHEMICALS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; PLACEBOS; PROTEASE INHIBITORS; QUALITY OF LIFE;

EID: 33745963397     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.12.020     Document Type: Article

References (33)

1. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br. Med. J. 303 (1991) 884-893
2. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-7
3. Piccart M.J., Bertelsen K., Stuart G., et al. Is cisplatin-paclitaxel (P-T) the standard in the first line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCIC and Scottish Intergroup experience. Proc. Am. Soc. Clin. Oncol. 16 (1997) 352a
4. Goetzl E., Banda M., and Leppert D. Matrix metalloproteinases in immunity. J. Immunol. 156 (1996) 1-4
5. Cawston T. Proteinases and inhibitors. Br. Med. J. 51 (1995) 385-401
6. De Clerck Y.A., Shimada H., Taylor S.M., et al. Matrix metalloproteinases and their inhibitors in tumor progression. Ann. N. Y. Acad. Sci. 732 (1994) 222-232
7. Brown P.D., and Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. 6 (1995) 967-974
8. John A., and Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res. 7 (2001) 14-23
9. Sakata K., Shigemasa K., Nagai N., et al. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int. J. Oncol. 17 (2000) 673-681
10. Davidson B., Goldberg I., Gotlieb W.H., et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlated with poor survival in ovarian carcinoma. Clin. Exp. Metastasis 17 (1999) 799-808
11. Schmalfeldt B., Prechtel D., Harting K., et al. Increased expression of matrix metalloproteinases MMP-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7 (2001) 2396-2404
12. Davidson B., Goldberg I., Gotlieb W.H., et al. The prognostic value of metalloproteinases and angiogenic factors in ovarian cancer. Mol. Cell. Endocrinol. 187 (2002) 39-45
13. Murphy G., Willenbrock F., Crabbe T., et al. Regulation of matrix metalloproteinase activity. Ann. N. Y. Acad. Sci. 732 (1994) 31-40
14. Levy D.E., and Ezrin AM. Matrix metalloproteinase inhibiting drugs. Emerg. Drugs 2 (1997) 205-230
15. Kluender H, Dixon B, VanZandt M. et al. Substituted 4-biarylbutyric acid derivatives as matrix metalloproteinase inhibitors. U.S. patent 5,861,428 granted to Bayer Corp. January 19, 1999.
16. Rowinsky E., Humphrey R., Hamond L.A., et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol. 18 (2000) 178-186
17. Grochow L., O=Reilly S., Humphrey R., et al. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566. Proc. Am. Soc. Clin. Oncol. 17 (1998) 213a [abstr]
18. Erlichman C., Adjei A., Alberts S., et al. Phase I study of BAY 12-9566-a matrix metalloproteinase inhibitor (MMPI). Proc. Am. Soc. Clin. Oncol. 17 (1998) 217a [abstr]
19. Hirte H., Goel R., Major P., Seymour L., Huan S., Stewart D., et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann. Oncol. 11 (2000) 1579-1584
20. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
21. Duivenvoorden W.C., Hirte H.W., and Singh G. Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study. Int. J. Cancer 15 (2001) 857-862
22. Moore M.J., Hamm J., Eisenberg P., Dagenais K., Hagan K., Fields A., et al. A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 19 (2000) 240a [abstr]
23. Grochow LB. Preclinical and clinical pharmacology of matrix metalloproteinase inhibitors (MMPIs). Ann. Oncol. 9 Suppl. 2 (1998) 75 [abstr]
24. Neri A., Goggin B., Kolis S., et al. Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor AG3340 in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice. Proc. Am. Assoc. Cancer Res. 39 (1998) 302 [abstr]
25. Wojtowicz-Praga S., Torri J., Johnson M., et al. Phase I trial of marismastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 16 (1998) 2150-2156
26. Hande K., Wilding G., Ripple G., et al. A phase I study of AG3340, a matrix metalloprotease (MMP) inhibitor, in patients having advanced cancer. Ann. Oncol. 9 suppl 2 (1998) 74 [abstr]
27. Krane S.M. Clinical importance of metalloproteinase and their inhibitors. Ann. N. Y. Acad. Sci. 732 (1994) 1-10
28. Bramhall S., Rosemurgy A., Brown P.D., et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19 (2001) 3447-3455
29. Bramhall S.R., Hallissey M.T., Whiting J., et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer 86 12 (2002) 1864-1870
30. Shepherd F.A., Giaccone G., Debruyne C., Hirsh V., Smylie M., Rubin S., et al. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC Study. Proc. Am. Soc. Clin. Oncol. 20 (2001) 11a [abstr]
31. Wagenaar-Miller R.A., Gorden L., and Matrisian L. Matrix metalloproteinases in colorectal cancer: is it worth talking about?. Cancer Metastasis Rev. 23 (2004) 119-135
32. Markman M., Liu P.Y., Wilczynski S., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial. J. Clin. Oncol. 21 13 (2003) 2460-2465
33. Douillard J., Petersen V., Shepherd F., et al. Randomized phase II study of BMS-275291 versus placebo in patients with stage IIIB or IV non-small cell lung cancer receiving paclitaxel plus carboplatin. National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.18. Eur. J. Cancer 37 Suppl 6 (2001) S19 [Abst 63]